> Details

Marazuela, Paula; Bonaterra-Pastra, Anna; Faura, Júlia; Penalba, Anna; Pizarro, Jesús; Pancorbo, Olalla; Rodríguez-Luna, David; Vert, Carla; Rovira, Alex; Pujadas, Francesc; Freijo, M. Mar; Tur, Silvia; Martínez-Zabaleta, Maite; Cardona Portela, Pere; Vera, Rocío; Lebrato-Hernández, Lucia; Arenillas, Juan F.; Pérez-Sánchez, Soledad; Montaner, Joan; Delgado, Pilar; Hernández-Guillamon, Mar

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage
  • Contributor: Marazuela, Paula; Bonaterra-Pastra, Anna; Faura, Júlia; Penalba, Anna; Pizarro, Jesús; Pancorbo, Olalla; Rodríguez-Luna, David; Vert, Carla; Rovira, Alex; Pujadas, Francesc; Freijo, M. Mar; Tur, Silvia; Martínez-Zabaleta, Maite; Cardona Portela, Pere; Vera, Rocío; Lebrato-Hernández, Lucia; Arenillas, Juan F.; Pérez-Sánchez, Soledad; Montaner, Joan; Delgado, Pilar; Hernández-Guillamon, Mar
  • imprint: MDPI AG, 2021
  • Published in: Journal of Clinical Medicine
  • Language: English
  • DOI: 10.3390/jcm10050989
  • ISSN: 2077-0383
  • Keywords: General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p>Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH.</jats:p>
  • Access State: Open Access